Why Target the Gut to Treat IgA Nephropathy?
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
It is more than 50 years since the first description of IgA nephropathy (IgAN) by the Parisian pathologist, Jean Berger.1 Over this time, IgAN became recognized as the most common pattern of glomerular disease worldwide.2 Despite the significant global burden of chronic and end-stage kidney disease associated with IgAN, there are currently no approved treatments.3 Standard of care continues to be supportive therapy, which focuses on optimal blood pressure control, a low-sodium diet, and maximum tolerated blockade of the renin-angiotensin-aldosterone system (Kidney Disease Improving Global Outcomes Glomerulonephritis Work Group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wyatt, R. J., & Julian, B. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1206793 · Cited by 1,222
Intensive supportive care plus immunosuppression in IgA nephropathy
Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415463 · Cited by 726
Self-citationNew strategies and perspectives on managing IgA nephropathy
Selvaskandan, H., Cheung, C. K., Muto, M., & Barratt, J. (2019) · Clinical and Experimental Nephrology · doi:10.1007/s10157-019-01700-1 · Cited by 83
Self-citation
Cited by
Wheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.033 · Cited by 420
“gov Identifier: NCT03643965).(31) Other potential therapeutic approaches, some of which are being assessed in ongoing trials, include inhibition of endothelin-1 (NCT04663204 and NCT04573478), inhibition of complement activation, and proteasome inhibitors.”
BackgroundLafayette, R., Kristensen, J., Stone, A., Floege, J., Tesař, V., Trimarchi, H., Zhang, H., Eren, N., Paliege, A., Reich, H. N., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01554-4 · Cited by 337
Self-citationBarratt, J., Lafayette, R., Kristensen, J., Stone, A., Cattran, D., Floege, J., Tesar, V., Trimarchi, H., Zhang, H., Eren, N., et al. (2023) · Kidney International · doi:10.1016/j.kint.2022.09.017 · Cited by 224
Self-citationThe pathogenesis of IgA nephropathy and implications for treatment
Cheung, C. K., Alexander, S., Reich, H. N., Selvaskandan, H., Zhang, H., & Barratt, J. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00885-3 · Cited by 222
Self-citationThe expanding role of biomarkers in the management of IgA nephropathy
Jain, K., & Rizk, D. V. (2026) · Kidney International Supplements · doi:10.1016/j.kisu.2026.01.004 · Cited by 6
Metadata
- Authors
- Barratt, J., Rovin, B. H., Cattran, D., Floege, J., Lafayette, R., Tesar, V., Trimarchi, H., & Zhang, H.
- Venue
- Kidney International Reports
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 5
- Issue
- 10
- Pages
- 1620-1624
- ISSN
- 2468-0249 (ISSN-L)
- OpenAlex
- W3080629152
- Cited by
- 95
- References
- 3
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.